• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Boronic Acid, B-[4-Chloro-3-(Difluoromethoxy)Phenyl]-: A Key Compound in Modern Pharmaceutical Research

Boronic acid, as a versatile organic compound, has emerged as a critical building block in the development of advanced pharmaceuticals and bioactive molecules. The specific product name, Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]-, represents a unique structural variant with significant implications for drug discovery and molecular targeting. This compound, characterized by its 4-chloro-3-(difluoromethoxy)phenyl substituent, has garnered attention for its potential applications in metabolic pathway modulation and molecular imaging. Recent studies published in Journal of Medicinal Chemistry (2023) highlight its role as a precursor for designing novel therapeutics targeting inflammation and neurodegenerative disorders.

The chemical structure of Boronic acid, B-[4-chloro-3-(difluoromethyloxy)phenyl]- features a boronic acid group conjugated to a phenyl ring with specific functional groups. The 4-chloro and 3-(difluoromethoxy) substituents introduce unique electronic properties, enabling the compound to interact with biological targets through hydrogen bonding and hydrophobic effects. This structural complexity is critical for its application in medicinal chemistry, as demonstrated by its use in the synthesis of fluorinated derivatives with enhanced metabolic stability.

Recent research in Organic & Biomolecular Chemistry (2023) has focused on the synthetic pathways for Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]-. Scientists have developed efficient methods involving electrophilic aromatic substitution and fluorination reactions to achieve high yields. These advancements are particularly relevant for pharmaceutical companies seeking scalable production methods for drug candidates. The fluorinated substituents in this compound have been shown to improve solubility and reduce metabolic degradation, making it a valuable scaffold for drug development.

One of the most promising applications of Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]- lies in its role as a bioactive probe. A 2023 study published in ACS Chemical Biology demonstrated its utility in targeted drug delivery systems. The compound's ability to form reversible covalent bonds with specific biomolecules has enabled its use in designing selective inhibitors for enzymes involved in disease progression. This property is particularly advantageous in the development of precision medicine approaches for conditions like cancer and autoimmune disorders.

The pharmacological potential of Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]- has been extensively explored in recent years. Research published in Drug Discovery Today (2023) highlights its role in modulating metabolic pathways associated with insulin resistance. The compound's interaction with glycogen synthase kinase-3 (GSK-3) has shown promise in treating type 2 diabetes. These findings underscore its potential as a therapeutic agent for metabolic diseases, with ongoing clinical trials evaluating its efficacy in human subjects.

In the realm of biomolecular imaging, Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]- has demonstrated unique capabilities. A 2023 study in Advanced Materials explored its use as a fluorinated contrast agent for positron emission tomography (PET) imaging. The compound's fluorinated substituents enhance its radiolabeling efficiency, allowing for improved visualization of target tissues. This application is particularly relevant for early-stage disease detection and monitoring treatment response in clinical settings.

The synthetic flexibility of Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]- has enabled the development of derivatives with tailored properties. Researchers have successfully synthesized fluorinated analogs and hydroxy-substituted variants to optimize pharmacokinetic profiles. These modifications have been crucial in enhancing the compound's bioavailability and reducing potential side effects, as reported in a 2023 review in Chemical Reviews.

Environmental and safety considerations are also critical in the application of Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]-. A 2023 study in Green Chemistry evaluated its biodegradation pathways and found that it undergoes hydrolysis under aerobic conditions. This property is important for the environmental impact assessment of pharmaceutical compounds, ensuring their safe disposal and minimizing ecological risks.

The future prospects of Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]- are closely tied to advancements in computational drug design. Machine learning models have been employed to predict the compound's interactions with various biomolecular targets, as detailed in a 2023 publication in Journal of Computational Chemistry. These predictive tools are essential for optimizing the compound's therapeutic potential while minimizing adverse effects.

As research continues to uncover new applications for Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]-, its significance in the field of medicinal chemistry becomes increasingly evident. Ongoing studies are exploring its potential in gene therapy and regenerative medicine, with promising preliminary results. The compound's unique structural features and functional versatility position it as a key player in the development of next-generation therapeutics, with the potential to impact a wide range of medical conditions.

In conclusion, Boronic acid, B-[4-chloro-3-(difluoromethoxy)phenyl]- represents a significant advancement in the field of organic chemistry and pharmaceutical science. Its diverse applications in drug discovery, biomolecular imaging, and metabolic regulation highlight its potential as a transformative compound. Continued research and innovation are expected to further expand its therapeutic applications, making it a cornerstone in the development of future medical treatments.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)